Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

By Kesteren Charlotte   Zandvliet Anthe   Karlsson Mats   Mathôt Ron   Punt Cornelis   Armand Jean-Pierre   Raymond Eric   Huitema Alwin   Dittrich Christian   Dumez Herlinde   Roché Henri   Droz Jean-Pierre   Ravic Miroslav   Yule S.   Wanders Jantien   Beijnen Jos   Fumoleau Pierre   Schellens Jan  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 225-234

Springer Publishing Company

Access to resources Recommend Favorite

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

By Marks Paul A  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 9, 2010-09 ,pp. : 1049-1066

Informa Healthcare

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas   Cherrington Julie M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents

By Casini Angela   Scozzafava Andrea   Supuran Claudiu T  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 9, 2002-09 ,pp. : 1307-1327

Informa Healthcare

Access to resources Recommend Favorite

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

By Keizer Ron   Zamacona Miren   Jansen Mendel   Critchley David   Wanders Jantien   Beijnen Jos   Schellens Jan   Huitema Alwin  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 140-152

Springer Publishing Company

Access to resources Recommend Favorite